Article

FDA panel expresses concern over OTC OAB patch

Merck has confirmed that the FDA Nonprescription Drug Advisory Committee proposed that the FDA consider labeling modifications as part of its review of oxybutynin transdermal system (Oxytrol) as an over-the-counter treatment for overactive bladder in women.

Related Videos
2 experts in this video
2 experts in this video
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.